Vera Therapeutics, INC. 8-K Filing
Ticker: VERA · Form: 8-K · Filed: Dec 10, 2025 · CIK: 1831828
| Field | Detail |
|---|---|
| Company | Vera Therapeutics, INC. (VERA) |
| Form Type | 8-K |
| Filed Date | Dec 10, 2025 |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $42.50, $260.9 m |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Vera Therapeutics, INC. (ticker: VERA) to the SEC on Dec 10, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (which registered Class A common stock, $0.001 par value per share VERA The Nasdaq); $42.50 (price to the public in the offering was $42.50 per share. The gross proceeds to the Co); $260.9 m (from the offering will be approximately $260.9 million, before deducting underwriting di).
How long is this filing?
Vera Therapeutics, INC.'s 8-K filing is 4 pages with approximately 1,050 words. Estimated reading time is 4 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 1,050 words · 4 min read · ~4 pages · Grade level 11.2 · Accepted 2025-12-10 17:18:59
Key Financial Figures
- $0.001 — which registered Class A common stock, $0.001 par value per share VERA The Nasdaq
- $42.50 — price to the public in the offering was $42.50 per share. The gross proceeds to the Co
- $260.9 m — from the offering will be approximately $260.9 million, before deducting underwriting di
Filing Documents
- d870139d8k.htm (8-K) — 31KB
- d870139dex11.htm (EX-1.1) — 211KB
- d870139dex51.htm (EX-5.1) — 11KB
- g870139g1210105330567.jpg (GRAPHIC) — 2KB
- g870139g1210110904636.jpg (GRAPHIC) — 2KB
- 0001193125-25-314430.txt ( ) — 432KB
- vera-20251209.xsd (EX-101.SCH) — 3KB
- vera-20251209_lab.xml (EX-101.LAB) — 18KB
- vera-20251209_pre.xml (EX-101.PRE) — 11KB
- d870139d8k_htm.xml (XML) — 4KB
Forward Looking Statements
Forward Looking Statements Certain statements contained in this report are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include, without limitation, statements about the Company's expectations with respect to the completion of the offering and the expected gross proceeds from the offering. Words such as "expect", "may," and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. For such statements, the Company claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from the Company's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, risks and uncertainties associated with market conditions, the satisfaction of customary closing conditions related to the offering, and the impact of macroeconomic and geopolitical events. Additional factors that could cause actual results to differ materially from those stated or implied by the Company's forward-looking statements are disclosed in the Company's filings with the SEC, including in the section captioned "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q and the prospectus supplement relating to the offering. These forward-looking statements represent the Company's judgment as of the time of this report. The Company disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law. Item9.01
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement by and among the Company, J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Cantor Fitzgerald & Co., dated December 9, 2025. 5.1 Opinion of Latham & Watkins LLP. 23.1 Consent of Latham & Watkins LLP (included in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vera Therapeutics, Inc. Dated: December 10, 2025 By: /s/ Marshall Fordyce Marshall Fordyce, M.D. Chief Executive Officer